Flputnam Investment Management Co. Buys 7,469 Shares of Abbott Laboratories $ABT

Flputnam Investment Management Co. boosted its position in Abbott Laboratories (NYSE:ABT) by 9.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 84,829 shares of the healthcare product maker’s stock after acquiring an additional 7,469 shares during the period. Flputnam Investment Management Co.’s holdings in Abbott Laboratories were worth $7,697,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Davidson Investment Advisors grew its holdings in shares of Abbott Laboratories by 3.6% in the 2nd quarter. Davidson Investment Advisors now owns 3,084 shares of the healthcare product maker’s stock valued at $280,000 after buying an additional 106 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Abbott Laboratories by 2.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 255,295 shares of the healthcare product maker’s stock worth $23,165,000 after acquiring an additional 7,059 shares during the period. Private Management Group Inc. lifted its position in Abbott Laboratories by 1.6% in the 2nd quarter. Private Management Group Inc. now owns 21,520 shares of the healthcare product maker’s stock valued at $1,953,000 after acquiring an additional 329 shares in the last quarter. Wedbush Securities Inc. boosted its stake in Abbott Laboratories by 2.7% in the 2nd quarter. Wedbush Securities Inc. now owns 65,216 shares of the healthcare product maker’s stock worth $5,918,000 after purchasing an additional 1,711 shares during the period. Finally, Spinnaker Trust raised its stake in shares of Abbott Laboratories by 1.7% in the 2nd quarter. Spinnaker Trust now owns 38,948 shares of the healthcare product maker’s stock valued at $3,534,000 after purchasing an additional 647 shares during the period. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ABT. UBS Group reduced their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Citigroup upped their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. Bank of America cut their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Finally, TD Cowen increased their target price on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $108.29 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The firm has a market cap of $187.38 billion, a P/E ratio of 35.05, a price-to-earnings-growth ratio of 2.02 and a beta of 0.59. The business’s 50 day moving average is $104.43 and its 200-day moving average is $100.12. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm earned $1.26 earnings per share. The company’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.